United Capital Financial Advisers LLC Boosts Stock Position in Steris PLC (NYSE:STE)

United Capital Financial Advisers LLC lifted its position in shares of Steris PLC (NYSE:STE) by 3.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 153,412 shares of the medical equipment provider’s stock after purchasing an additional 5,302 shares during the period. United Capital Financial Advisers LLC owned 0.18% of Steris worth $22,840,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Ropes Wealth Advisors LLC purchased a new stake in shares of Steris during the second quarter worth about $26,000. Evolution Wealth Advisors LLC purchased a new stake in shares of Steris during the second quarter worth about $27,000. Krane Funds Advisors LLC purchased a new stake in shares of Steris during the second quarter worth about $27,000. Farmers & Merchants Investments Inc. purchased a new stake in shares of Steris during the second quarter worth about $33,000. Finally, Cullen Frost Bankers Inc. boosted its holdings in shares of Steris by 114.4% during the second quarter. Cullen Frost Bankers Inc. now owns 253 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 135 shares during the period. Institutional investors own 88.04% of the company’s stock.

STE traded down $3.62 on Friday, hitting $144.33. The company had a trading volume of 356,717 shares, compared to its average volume of 455,768. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.41 and a quick ratio of 1.87. Steris PLC has a 52-week low of $99.14 and a 52-week high of $156.66. The stock has a fifty day simple moving average of $151.14 and a 200-day simple moving average of $137.81. The firm has a market capitalization of $11.99 billion, a P/E ratio of 29.51 and a beta of 0.94.

Steris (NYSE:STE) last issued its quarterly earnings data on Monday, August 5th. The medical equipment provider reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.12. Steris had a net margin of 11.22% and a return on equity of 13.80%. The business had revenue of $696.80 million during the quarter, compared to analyst estimates of $674.12 million. During the same period last year, the business posted $1.00 earnings per share. Steris’s quarterly revenue was up 9.1% compared to the same quarter last year. Equities research analysts expect that Steris PLC will post 5.46 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 26th. Shareholders of record on Tuesday, September 10th will be issued a $0.37 dividend. The ex-dividend date of this dividend is Monday, September 9th. This is a positive change from Steris’s previous quarterly dividend of $0.34. This represents a $1.48 annualized dividend and a yield of 1.03%. Steris’s dividend payout ratio (DPR) is 30.27%.

In other Steris news, insider Michael J. Tokich sold 22,000 shares of the firm’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $143.70, for a total value of $3,161,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Renato Tamaro sold 2,065 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $153.15, for a total transaction of $316,254.75. The disclosure for this sale can be found here. Insiders sold 151,175 shares of company stock valued at $22,688,470 over the last 90 days. 2.36% of the stock is currently owned by company insiders.

Separately, JMP Securities increased their target price on shares of Steris from $135.00 to $150.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 22nd. Five investment analysts have rated the stock with a buy rating, Steris has an average rating of “Buy” and an average target price of $148.20.

About Steris

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

See Also: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris PLC (NYSE:STE).

Institutional Ownership by Quarter for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.